EMA Belinostat is designated as the treatment of peripheral T-cell lymphoma orphan drugs
Topotarget pharmaceutical company claims, belinostat has been designated as the European Commission orphan drug for the treatment of peripheral T-cell lymphoma (PTCL). Belinostat is a small molecule histone deacetylase (HDAC) inhibitor, in patients with relapsed or refractory PTCL Phase III clinical trials (BELIEF). Spectrum Pharmaceuticals, Inc. Topotarget obtained in North America and India to jointly develop and commercialize belinostat rights. In September this year, Topotarget called Spectrum second half of 2012 the company plans to submit to the FDA a New Drug Application belinostat. Belinostat has been designated by the FDA orphan drug designation for the treatment of PTCL, and enter the fast-track channels.
EMA Belinostat is designated as the treatment of peripheral T-cell lymphoma orphan drugs
ReplyDeleteTopotarget pharmaceutical company claims, belinostat has been designated as the European Commission orphan drug for the treatment of peripheral T-cell lymphoma (PTCL). Belinostat is a small molecule histone deacetylase (HDAC) inhibitor, in patients with relapsed or refractory PTCL Phase III clinical trials (BELIEF). Spectrum Pharmaceuticals, Inc. Topotarget obtained in North America and India to jointly develop and commercialize belinostat rights. In September this year, Topotarget called Spectrum second half of 2012 the company plans to submit to the FDA a New Drug Application belinostat. Belinostat has been designated by the FDA orphan drug designation for the treatment of PTCL, and enter the fast-track channels.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Selumetinib
Galanthamine hydrobromide
MK-0974
OSU-03012
Celecoxib
Iguratimod
Etodolac
URB-597
PF-04457845
PF-3845